Introduction {#Sec1}
============

Around 10^\^12^ (trillion) complex microbial communities composed of fungi, yeasts, viruses and bacteria reside in the digestive tract, which constitute the human microbiome (HMB) (Marchesi et al. [@CR18]). Its metabolism as well as its genetic set interacts with the host organism defining a close symbiotic relationship (Fischbach and Segre [@CR6]). As a result, the bacterial composition mirrors the sophisticated commensality interplay that is established with the host organism and within the microbial community (Thursby and Juge [@CR34]; Khangwal and Shukla [@CR13]). Intestinal HMB changes with aging and metabolic disorder, and may contribute to the decline of nutrients' absorption (Dahiya et al. [@CR4]; Kastl et al. [@CR12]). It has been shown that by proper nutritional intervention, HMB can be restored and balanced sustaining eubiosis (Nagpal et al. [@CR21]; Salazar et al. [@CR29]; Wu and Wu [@CR38]). Eubiosis is also re-established by antiviral therapy in persistent hepatitis B virus (HBV) infection mouse model (Li et al. [@CR15]). HMB is capable of guaranteeing the well-being of the entire organism and its role is essential for the immune system of the host organism (Wu and Wu [@CR38]; Mu et al. [@CR20]). Environmental factors, poor lifestyles, psycho-physical stress, overnutrition, and pharmacological treatments are able to modify HMB, defining the dysbiosis (Karl et al. [@CR11]). This latter condition is often linked to the lack of intestinal homeostasis which in turn correlates to a wide range of inflammatory conditions (Wen and Duffy [@CR37]). Current knowledge concerning intestinal HMB, using test based on 16S rRNA gene target, points out to the existence of a community of almost 1000 bacterial species classified into five phyla: *Actinobacteria*, *Bacteroidetes*, *Firmicutes*, *Proteobacteria* and *Verrucomicrobia* (Rajilic-Stojanovic M and de Vos WM, [@CR25]). The results achieved thus far via high-throughput sequencing (HTS) platforms are very interesting, but the workflow, which includes the library preparation protocols and the enzymatic amplification of the nucleic acid, could lead to different results among the HTS platform used (Salipante et al. [@CR30]; D'Amore et al. [@CR5]; Loman et al. [@CR17]; Lam [@CR14]; Quail et al. [@CR24]; Clooney et al. [@CR3]; Mohammadi et al. [@CR19]). Besides that, sample collection and bacterial DNA extraction as well as the 16S rRNA gene target region represent other important points in the assessment of intestinal HMB (Pollock et al. [@CR23]; Rintala et al. [@CR26]). Therefore, concerns about using HMB analysis is still debated, limiting it to routinely clinical practice (Pollock et al. [@CR23]). In this framework, the assessment of the intestinal HMB in the medical setting may be helpful to dissect symptoms such as episodic colitis attack, diarrhea, constipation, flatulence, and intestinal discomfort (Chichlowski and Rudolph [@CR2]; Simrén et al. [@CR32]). Moreover, intestinal HMB analysis can be fundamental to develop therapeutic and personalized nutritional interventions (Seo et al. [@CR31]). In this work, we attempted to overcome these concerns. To minimize experimental variation, fecal samples were collected and stored with OMNI gene GUT, which proved as a reliable and convenient system to study intestinal HMB (Panek et al. [@CR22]). We performed bacterial DNA extraction with automatic system MagCore HF16 Plus with some modification to improve DNA yield; to avoid library preparation, we performed direct hybridization with n-counter flex DX. To evaluate dysbiosis, fecal occult blood (FOB) samples were collected from patients enrolled via a clinical trial. Of note, several inflammatory intestinal disorders are related to FOB which is not strictly related to colon cancer (Walker [@CR36]; Libby et al. [@CR16]). In this scenario, we have designed in July 2017 the first custom panel "CDR_CNV_Bc_miCrobioTA22586" with 79 bacteria 16S rRNA target genes representative of gut health and impaired in gut inflammation status (Tarallo et al. [@CR33]). *Alicyclobacillus acidophilus*, *Rhizobium radiobacter* and *Salinibacter ruber* are not present in the human gut and were used as negative control of human microbiota bacteria 16S rRNA gene. ACTB, GAPDH and HDAC3 genes were used for monitoring human DNA contamination.

Materials and methods {#Sec2}
=====================

Study design, sample collection and HMB community {#Sec3}
-------------------------------------------------

Study design and analytical workflow are shown in Fig. [1](#Fig1){ref-type="fig"}. Subjects enrolled were divided into two groups: healthy-negative for fecal occult blood (herein indicated as N-FOB; *n* = 48) and positive for fecal occult blood (herein indicated as P-FOB; *n* = 48). DNA extraction and/or genomic analysis was carried out for N-FOB *n* = 35 and P-FOB *n* = 35 samples, due to low amount of starting material.Fig. 1Study design and analytical workflow. Initially, 48 samples for each group, N-FOB, and P-FOB were collected, 13 samples for each group resulted in a low amount of fecal material. Therefore, DNA extraction for genomic analysis was carried out on 35 samples. Hybridization was performed for 22 h and cartridges were posed into the prep station for 3 h washing and then read to the digital counter for a further 5 h. Then *n*-solver software was used for the analysis

Clinical data are reported in Table [1](#Tab1){ref-type="table"}. The clinical trial was registered at <https://clinicaltrials.gov/ct2/show/NCT03388424>. This study was authorized by the ethical committee of University of Catanzaro (protocol \#287, November 2017) and informed consent was obtained from each patient. All procedures were conducted according to the principles expressed in the Declaration of Helsinki and the Guideline for Good Clinical Practice.Table 1Clinical data of enrolled subjectsSampleAge (years)MaleFemaleBlood amount in stool sample and its percentageN-FOBRange: 30--701830Absence of occult blood in stoolP-FOB\*Range: 50--702325− 100 to 300 ng/ml: 82%− 300 to 600 ng/ml: 10% \> 800 ng/ml: 8%\*Data from f-Hb (OC-Sensor Diana-Eiken Chemical-Tokyo)

0.5--1 g of fresh feces were collected in OMNI gene-GUT OMR 200 (DNA Genotek Inc, Ottawa, Canada). The stool samples were then carefully mixed with 2 mL of stabilization buffer in the provided tube and stored at room temperature.

DNA extraction and quantification {#Sec4}
---------------------------------

DNA extraction was performed by automatic system MagCore HF16 Plus. Briefly, 2 mL of feces samples was first exposed to 2 h of lysozyme (final concentration 250 µg/ml) treatment at 37 °C, then digested with Proteinase K solution (10 mg/ml, in GT buffer) at 65 °C for 3 h. Samples were centrifuged and the bacterial pellet was used for microbial DNA isolation by MagCore protocol cartridge 401 and carrier-RNA or cartridge 202.

The DNA quantity and quality measurements were performed on Qubit 3.0 using the Qubit dsDNA HS (High Sensitivity Assay by Thermo Fisher Scientific), based on the fluorescence readouts.

Microbiome panel design, NanoString sample preparation and nSolver™ rcc file acquisition {#Sec5}
----------------------------------------------------------------------------------------

Genomic DNA ID from Taxonomy for 16S rRNA gene of 79 bacterial strains was identified, of which three are not present in the human gut and three belong to the host DNA. The panel details are reported in Supplementary Table 1.

For the n-counter flex DX of NanoString Technology, 400 ng of 16S rRNA gene was used as input. After 2 h of AluI digestion at 37 °C, the sample was then hybridized with CodeSet (Supplementary File 1) for 22 h at 65 °C.

The unhybridized CodeSet was removed with automated purification performed on an nCounter Prep Station, and the remaining target probe complexes were transferred and bound to an imaging surface as previously described (Panek et al. [@CR22]; Geiss et al. [@CR7]). Counts of the two reporter probes were tabulated for each sample by the nCounter Digital Analyzer.

NanoString reproducibility, robustness and Clostridium difficile testing with GeneExpert--Cepheid™ {#Sec6}
--------------------------------------------------------------------------------------------------

The reproducibility of our set of experimental tests was monitored through the negative (AH \# 8) and positive (AF \# 6) control probes include in the panel by NanoString, as well as probe value for 12 samples were obtained with two different n-counter flex machine included in the panel and reported in the Supplementary Table 3 as count numbers. The robustness of the technology for the clinical sample was already studied (Veldman-Jones et al. [@CR35]). Finally, to corroborate the proposed experiments, some samples were randomly (1:4) analyzed with a common technology (GeneExpert---Cepheid GXCDIFFBT-CE-10) for *Clostridium difficile* used in molecular microbiology clinical practice (Supplementary Fig. 1).

Statistical analysis {#Sec7}
--------------------

Unless indicated, statistical significance was determined by a two-tailed Student's *t* test with suitable multiple comparison correction. *p* value of \< 0.05 was regarded as significant. Results are expressed as mean ± SD. A coefficient of variation (CV) of 60% was chosen as cutoff into the *n*-solver software analysis. CV is used for comparison between data sets with different units or widely different means. One sample from healthy subjects (N-FOB) was excluded due to the presence of a warning red flag in the n-solver analysis.

Results and discussion {#Sec8}
======================

The complex interaction between organism and microbiome, in both physiological and pathophysiological conditions, has attracted interest from the scientific community either for personalized medicine or to develop probiotics supplement to relieve gut nuisance (Salazar et al. [@CR29]; Wu and Wu [@CR38]; Mu et al. [@CR20]; Wen and Duffy [@CR37]; Seo et al. [@CR31]; Dahiya et al. [@CR4]; Yadav et al. [@CR39]). Furthermore, intestinal discomfort is characterized by pain and gut inflammation. The panel design was fulfilled for intestinal discomfort and according to the scientific literature (Chichlowski and Rudolph [@CR2]; Simrén et al. [@CR32]).

Currently in the experimental pipeline of 16S rRNA gene sequence with HTS, each procedural step introduces a variation that could influence the final output (Pollock et al. [@CR23]). Therefore, there is an unmet need for standardization of methodology which would enable a reliable and reproducible analysis of valuable human biological samples for studying gut microbiota (Pollock et al. [@CR23]; Rintala et al. [@CR26]; Panek et al. [@CR22]).

Herein, we show that the direct detection of 16S rRNA target gene via hybridization method allows us to appreciate the variation of biodiversity (Fig. [2](#Fig2){ref-type="fig"} and Supplementary Table 2) within the collected samples (Table [1](#Tab1){ref-type="table"}). The designed panel based on 16S rRNA gene was suitable for n-counter flex platform considering also the haploid nature of the bacteria DNA (Geiss et al. [@CR7]; Griswold [@CR8]).Fig. 2Heat map and hierarchical clustering of N-FOB (*n* = 34), and P-FOB (*n* = 35) based on the differentially present bacteria 16S rRNA in log2 ratios. The color intensity represents changes in bacteria variation, ranging from − 3.51 to 5.582. In the analysis, red represents low bacteria abundance and green represents high bacteria abundance. Black represents unchanged bacteria presence as evident by the color reference. *n*-Solver software was used. A coefficient of variation of 60% was applied

The minimum input of nucleic acid used in this study was 400 ng. The DNA extraction was performed as described in "[Materials and methods](#Sec2){ref-type="sec"}". The highest DNA yields (an enrichment of DNA from 40- to 48-fold) were obtained using the cartridge 401 modified protocol compared to cartridge 202 (Table [2](#Tab2){ref-type="table"}).Table 2Comparison of total DNA extraction from stool samples between 202 (G1) and 401 (G2) cartridge protocolsG1Total DNA ng/µl\
\# 202 cartridgeG2Total DNA ng/µl\
\# 401 cartridgeEnrichment G2 vs G1*p* value11.5227 ± 0.0148161.8962 ± 0.0176\*\*\*40.65\< 0.00121.3951 ± 0.0080262.4069 ± 0.0142\*\*\*44.73\< 0.00131.2539 ± 0.0093360.5769 ± 0.0167\*\*\*48.31\< 0.00141.0769 ± 0.0092452.1298 ± 0.0212\*\*\*48.40\< 0.001

16S rRNA gene array profiles generate a heat map and hierarchical clustering based on the most differentiated biodiversity as shown in Fig. [2](#Fig2){ref-type="fig"}. The analyzed data set is composed of 5.530 count number of 16S rRNA target, related to 79 bacteria recognized by the best hybridization probe and detected in 69 different subjects.

The samples were classified according to two clusters: P-FOB (in green) and N-FOB (in red) negative control (in black). Of 79 bacteria, 32 displayed variation between the two clusters. The differential bacteria distribution in P-FOB compared to N-FOB showed an increased presence of part of them in P-FOB subjects. The agglomerative cluster of the heat map with a dendrogram tree showed an obvious clustering of 16S rRNA-specific bacteria genes that ranged from − 3.51 up to 5.582 in P-FOB subjects, as illustrated in Fig. [2](#Fig2){ref-type="fig"}. Red indicates decrease up to − 3.51 of 16S rRNA-specific bacteria genes, while green indicates an increase up to 5.582 of 16S rRNA-specific bacteria genes.

Data from the heat map, reported in Fig. [2](#Fig2){ref-type="fig"} and in Supplementary Table 2, show that bacteria biodiversity between the two groups is greatly different. The information obtained is in agreement with those reported in a recently paper from Tarallo et al. ([@CR33]).

In particular, bacteria belonging to Bacteroidetes phylum was recently reviewed for its role in metabolic disease, among which *Prevotella* assumes an important meaning (Johnson et al. [@CR9]). Likewise, Proteobacteria phylum such as *Helicobacter pylori*, *Desulfovibrio vulgaris*, *Desulfovibrio fairfieldensis,* *Desulfovibrio desulfuricans*, *Escherichia fergusonii*, and *Haemophiilus parainfluenzae* are higher in pathophysiological gut status according to our heat map results and previous studies (Tarallo et al. [@CR33]; Rizzatti et al. [@CR27]). Additionally, Libby et al. (2019) pointed out a significant correlation for fecal blood presence and the increasing risk of dying from circulatory, respiratory and digestive diseases (excluding colorectal cancer) as well as neuropsychological, blood and endocrine disease (Walker [@CR36]). Therefore, defining the nature of dysbiosis for the presence of blood in feces could prevent these risks also combining biotechnological intervention (Khangwal and Shukla [@CR13]). The observations described here have two possible implications concerning gut dysbiosis. First, the dysbiosis in the microbiome linked to blood feces presence might also be used to explore the underlying reasons for different patterns of mortality in different populations across the world. Second, the proper prebiotics/probiotics intervention could modify microbiome dysbiosis and possibly blood feces biomarker to reduce the risk of premature mortality.

In addition, *Firmicutes* phylum abundances were significantly different in cancer stool sample compared to healthy or the adenoma sample (Tarallo et al. [@CR33]). In this context,, results from our trial showed a higher presence of *Clostridium difficile* that displayed about 70% of low presence in N-FOB compared to P-FOB subjects (21/34 red dots of N-FOB) vs 24/35 green dots in P-FOB). These data assume particular interest in preventing *Clostridium difficile* infection, where in extreme condition fecal microbiome transplantation can occur (Juul et al. [@CR10]). The importance of testing microbiome is becoming more evident, especially considering that the gut axis interaction involves several organs (brain, kidney, liver, bone, skin, adipose tissue and heart) (Ahlawat and Sharma [@CR1]). Consequently, comprehensive information of the types of microbes that reside in the human gut is necessary before any kind of pharmacological intervention that attempts to alter the microbiome. Our methods could be applied successfully on long-term archived fecal sample sets, originally collected for testing fecal blood, to stratify patients and could be used for microbiome-based early biomarker discovery for gut health (Rounge et al. [@CR28]). Of note, this is the first time that direct hybridization with n-counter flex DX platform was applied to microbiome studies and although second generation of platform already exists, both produced equivalent signals and signal deviations (Yu et al. [@CR40]). Finally, it is important to underline that using two different n-counter flex machines, we obtained similar results (*p* \> 0.05) showing both, reproducibility and robustness of the n-counter technology. Moreover, comparing the results obtained using a microbiological clinical diagnostic tool for*Clostridium difficile* with the results obtained from n-counter flex DX, the presence of this bacterium in P-FOB subjects was successfully reported, corroborating our results.

Conclusions {#Sec9}
===========

The complex interaction between organism and microbiome, both in the physiology and in the pathophysiology, has aroused much interest in the last years. The microbiome represents one of the most significant new topics in the biomedical field that has concretely entered the medical/therapeutic field. This is the first study undertaken to determine HMB by direct hybridization using n-counter flex DX technology. This approach gives a useful tool for robust diagnostic/screening profiles of the microbiome. It is an innovative and exportable diagnostic model in the laboratory medicine practice. Furthermore, as the HMB panel could have strength up to 800 bacteria, this technology could lead to new biomarkers' discovery of microbiome and pave the way for the identification of therapeutic targets for human well-being.
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